Abstract

Retrospective Study

The outcome of autologous hematopoietic stem cell transplantation in patients with multiple myeloma. The experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia

Khalid Ahmed Al-Anazi*, Mutahar E, Abduljalil O, Kanfer S, Kaloyannidis P, Estanislao A, Apostolidis I, Almokhtar N, Darweesh M, Abdulbaqi M, Alenazi W, Alshammasi Z, Alshaibani Z, Kawarie M, Raslan H, Albahrani A, Alsaber A, AlMulhem N, Dridi W, Aldayel A, Alrabeh R, Alshami A, Ayyad A, Abu Rahma F, Lardizabal J, Salam A, Haque K, Alsagheir A and Alhashmi H

Published: 29 September, 2022 | Volume 6 - Issue 1 | Pages: 019-028

Background: Aautologous hematopoietic stem cell transplants (HSCT) is the standard of care for newly diagnosed patients with multiple myeloma (MM) who are eligible for autologous transplantation. Although cryopreservation is routinely employed, autologous HSCT can be performed using non-cryopreserved stem cells.
Methods and materials: A retrospective study of patients with MM who received autologous HSCT between the 10th of October 2010 and the 31st of January 2022 at King Fahad Specialist Hospital (KFSH) in Dammam, Saudi Arabia was performed.
Results: Over 11 years and 113 days, a total of 135 autologous HSCTs were performed for 119 patients with MM at our institution. Single autologous HSCTs were performed for 119 patients, while 16 of these patients received either planned tandem autologous transplants or second autografts due to either progression or relapse of their myeloma. The median age of patients with MM at autologous HSCT was 51.5 years. At presentation of their MM, the following high-risk (HR) features were encountered: stage III disease according to the revised international scoring system (RISS) in 12.3%; adverse cytogenetics in 31.93% of patients; advanced bone disease in 60.50%; and renal dysfunction or failure in 11.76% of patients. 
A total of 104 autologous HSCTs (77.04%) were performed without cryopreservation while 31 autografts (22.96%) were performed using cryopreserved apheresis stem cell products. Additionally, 54 autologous HSCTs (40.00%) were done at outpatient while 81 autografts (60.00%) were performed in an inpatient setting. Survival for 100 days post-HSCT for all patients with MM who received autologous transplants including those done at outpatient was 100%. The 4 years overall survival (OS) an progression-free survival (PFS) for patients with MM who received non- cryopreserved or fresh autologous HSCTs were 82% and 68% respectively.
Conclusion: Autologous HSCT without cryopreservation is safe, and feasible and can lead to short-term as well as long-term outcomes that are comparable to autologous transplantation with cryopreservation. Non- cryopreserved autologous grafts allow the performance of autologous transplants in an outpatient setting to save beds and reduce costs.

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001027 Cite this Article Read Full Article PDF

Keywords:

Multiple myeloma; Autologous hematopoietic stem cell transplantation; Non-cryopreservation; Outpatient transplantation

References

  1. Małecki B, Gil L, Dytfeld D. Role of transplantation in treatment of multiple myeloma in era of novel agents. Acta Haematol Pol. 2021; 52(2): 77-84. doi: 10.5603/AHP.2021.0013.
  2. Ozaki S, Shimizu K. Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future. Biomed Res Int. 2014;2014:394792. doi: 10.1155/2014/394792. Epub 2014 Feb 20. PMID: 24719860; PMCID: PMC3956410.
  3. Al-Anazi KA. Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation. Bone Marrow Res. 2012;2012:917361. doi: 10.1155/2012/917361. Epub 2012 May 28. PMID: 22693672; PMCID: PMC3368160.
  4. Du J, Zhuang J. Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020. Chronic Dis Transl Med. 2021 Aug 31;7(4):220-226. doi: 10.1016/j.cdtm.2021.08.003. PMID: 34786541; PMCID: PMC8579022.
  5. Charliński G, Jurczyszyn A. Multiple myeloma - 2020 update on diagnosis and management. NOWOTWORY J Oncol 2020; 70: 85-91.
  6. Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int. 2016 Jul 11;113(27-28):470-6. doi: 10.3238/arztebl.2016.0470. PMID: 27476706; PMCID: PMC4973001.
  7. Al-Anazi K. Hematopoietic stem cell transplantation in multiple myeloma in the era of novel therapies. In: Update on Multiple Myeloma. Edited by Khalid Al-Anazi. London. Intech Open. 2018. doi: 10.5772/intechopen.79999
  8. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022 Aug;97(8):1086-1107. doi: 10.1002/ajh.26590. Epub 2022 May 23. PMID: 35560063; PMCID: PMC9387011.
  9. Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021 Jan 20;9(1):3. doi: 10.3390/medsci9010003. PMID: 33498356; PMCID: PMC7838784.
  10. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016 Dec;43(6):676-681. doi: 10.1053/j.seminoncol.2016.11.004. Epub 2016 Nov 10. PMID: 28061985; PMCID: PMC5283695.
  11. Joshua DE, Bryant C, Dix C, Gibson J, Ho J. Biology and therapy of multiple myeloma. Med J Aust. 2019 May;210(8):375-380. doi: 10.5694/mja2.50129. Epub 2019 Apr 23. PMID: 31012120.
  12. Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019 Apr 8;9(4):44. doi: 10.1038/s41408-019-0205-9. PMID: 30962422; PMCID: PMC6453900.
  13. Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J. 2022 Mar 28;12(3):47. doi: 10.1038/s41408-022-00645-1. PMID: 35347107; PMCID: PMC8960754.
  14. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020 Sep 28;10(9):94. doi: 10.1038/s41408-020-00359-2. PMID: 32989217; PMCID: PMC7523011.
  15. Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. JCO Oncol Pract. 2020 Feb;16(2):56-66. doi: 10.1200/JOP.19.00335. PMID: 32045556.
  16. Drozd-Sokołowska J, Gras L, Zinger N, Snowden JA, Arat M, Basak G, Pouli A, Crawley C, Wilson KMO, Tilly H, Byrne J, Bulabois CE, Passweg J, Ozkurt ZN, Schroyens W, Lioure B, Colorado Araujo M, Poiré X, Van Gorkom G, Gurman G, de Wreede LC, Hayden PJ, Beksac M, Schönland SO, Yakoub-Agha I. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT. Bone Marrow Transplant. 2022 Apr;57(4):633-640. doi: 10.1038/s41409-022-01592-y. Epub 2022 Feb 15. PMID: 35169284; PMCID: PMC8993690.
  17. Rajkumar SV. Clinical features, laboratory manifestations, and diagnosis of multiple myeloma. Up to Date 2018. Edited by Kyle RA, Connor RF.      
  18. Ricciuti G, Falcone A, Cascavilla N, Martinelli G, Cerchione C. Autologous stem cell transplantation in multiple myeloma. Panminerva Med. 2020 Dec;62(4):220-224. doi: 10.23736/S0031-0808.20.04114-2. Epub 2020 Sep 21. PMID: 32955179.
  19. Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, Schinke C, Thanendrarajan S, Davies FE, Hoering A, Morgan GJ. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020 Jan 28;4(2):422-431. doi: 10.1182/bloodadvances.2019000524. PMID: 31990333; PMCID: PMC6988393.
  20. Piriyakhuntorn P, Tantiworawit A, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L. Outcomes of Non-Cryopreserved Versus Cryopreserved Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma. Ann Transplant. 2020 Dec 11;25:e927084. doi: 10.12659/AOT.927084. PMID: 33303730; PMCID: PMC7737409.
  21. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021 Dec 1;106(12):3211-3214. doi: 10.3324/haematol.2021.279179. PMID: 34407606; PMCID: PMC8634193.
  22. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ; Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr;88(4):360-76. doi: 10.1016/j.mayocp.2013.01.019. Erratum in: Mayo Clin Proc. 2013 Jul;88(7):777. Stewart, Keith [corrected to Stewart, A Keith]. PMID: 23541011.
  23. Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996 Jun;2(6):947-52. PMID: 9816255.
  24. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jul;15(7):812-6. doi: 10.1016/j.bbmt.2009.03.021. PMID: 19539212; PMCID: PMC4112358.
  25. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):472-6. doi: 10.1016/j.clml.2015.03.003. Epub 2015 Mar 27. PMID: 25963284; PMCID: PMC4516682.
  26. Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant. 2017 Dec;52(12):1616-1622. doi: 10.1038/bmt.2017.198. Epub 2017 Sep 18. PMID: 28920949; PMCID: PMC5859934.
  27. Al-Anazi KA, Mokhtar N, Kawari M, AlHashmi H, Abduljalil O, Alshaibani E, et al. A young patient with refractory multiple myeloma and dialysis-dependent renal failure has been cured by noncryopreserved autologous stem cell transplantation followed by liverelated kidney transplantation. J Stem Cell Bio. Transplant. 2017; 1 (2:13). doi: 10.21767/ 2575-7725.100013
  28. Katragadda L, McCullough LM, Dai Y, Hsu J, Byrne M, Hiemenz J, May S, Cogle CR, Norkin M, Brown RA, Wingard JR, Chang M, Moreb JS. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience. Clin Transplant. 2016 Aug;30(8):894-900. doi: 10.1111/ctr.12762. Epub 2016 Jun 29. PMID: 27219740.
  29. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005 Jul;75(1):27-33. doi: 10.1111/j.1600-0609.2005.00446.x. PMID: 15946307.
  30. Antlanger M, Dust T, Reiter T, Böhm A, Lamm WW, Gornicec M, Willenbacher E, Nachbaur D, Weger R, Rabitsch W, Rasoul-Rockenschaub S, Worel N, Lechner D, Greinix H, Keil F, Gisslinger H, Agis H, Krauth MT. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer. 2018 Oct 20;18(1):1008. doi: 10.1186/s12885-018-4926-0. PMID: 30342509; PMCID: PMC6195957.
  31. Wannesson L, Panzarella T, Mikhael J, Keating A. Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Ann Oncol. 2007 Apr;18(4):623-32. doi: 10.1093/annonc/mdm069. Epub 2007 Mar 12. PMID: 17355952.
  32. Hechler G, Weide R, Heymanns J, Köppler H, Havemann K. Storage of noncryopreserved periphered blood stem cells for transplantation. Ann Hematol. 1996 May;72(5):303-6. doi: 10.1007/s002770050176. PMID: 8645742.
  33. Sarmiento M, Ramírez P, Parody R, Salas MQ, Beffermann N, Jara V, Bertín P, Pizarro I, Lorca C, Rivera E, Galleguillos M, Ocqueteau M, Sánchez-Ortega I, Patiño B, Sureda A. Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy. Bone Marrow Transplant. 2018 Aug;53(8):960-966. doi: 10.1038/s41409-018-0117-5. Epub 2018 Feb 13. PMID: 29440738.
  34. Ramzi M, Zakerinia M, Nourani H, Dehghani M, Vojdani R, Haghighinejad H. Non-cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience. Clin Transplant. 2012 Jan-Feb;26(1):117-22. doi: 10.1111/j.1399-0012.2011.01432.x. Epub 2011 Sep 15. PMID: 21919958.                                     
  35. Kayal S, Sharma A, Iqbal S, Tejomurtula T, Cyriac SL, Raina V. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):140-7. doi: 10.1016/j.clml.2013.09.001. Epub 2013 Sep 28. PMID: 24342104.
  36. Bekadja MA, Brahimi M, Osmani S, Arabi A, Bouhass R, Yafour N, Entasoltan B, Rasheed W, Attaf F. A simplified method for autologous stem cell transplantation in multiple myeloma. Hematol Oncol Stem Cell Ther. 2012;5(1):49-53. doi: 10.5144/1658-3876.2012.49. PMID: 22446610.
  37. Jasuja SK, Kukar (jasuja) N, Jain R, Bhateja A, Jasuja A, Rohit Jain. A simplified method at lowest cost for autologous, non-cryopreserved, unmanipulated, peripheral hematopoietic stem cell transplant in multiple myeloma and non-Hodgkin's lymphoma: Asian scenario. J Clin Oncol. 2010; 28(15): ė18545
  38. Mutahar E, Al-Anazi KA. Engraftment syndrome: An updated review. J Stem Cell Transplant. 2017; 1(3):16. doi: 10.21767/2575-7725.100016
  39. Kanfar S, Al-Anazi KA. Autologous graft versus host disease: An updated review. Ann Stem Cells Regen Med. 2018; 1(1): 1002
  40. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997 Feb 1;89(3):789-93. PMID: 9028309.
  41. Putkonen M, Rauhala A, Itälä M, Kauppila M, Pelliniemi TT, Remes K. Double versus single autotransplantation in multiple myeloma; a single center experience of 100 patients. Haematologica. 2005 Apr;90(4):562-3. PMID: 15820960.
  42. Cavo M, Petrucci MT, Di Raimondo F, Zamagni E, Gamberi B, Crippa C, et al. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood. 2016; 128, 991. doi: 1182/blood. V128.22.991.991                                                                                          
  43. Cavo M, Gay FM, Patriarca F, Zamagni E, Montefusco V, Dozza L, et al. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/H095 study. Blood 2017; 130:401. doi: 10.1182/blood.V130. Suppl_1.401.401
  44. Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras RP, Cahn JY, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 Nov;25(11):2134-2142. doi: 10.1016/j.bbmt.2019.07.004. Epub 2019 Jul 6. PMID: 31288095.
  45. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003 Dec 25;349(26):2495-502. doi: 10.1056/NEJMoa032290. Erratum in: N Engl J Med. 2004 Jun17;350(25):2628. PMID: 14695409.
  46. Martino M, Lemoli RM, Girmenia C, Castagna L, Bruno B, Cavallo F, Offidani M, Scortechini I, Montanari M, Milone G, Postacchini L, Olivieri A. Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplant. 2016 Aug;51(8):1032-40. doi: 10.1038/bmt.2016.79. Epub 2016 Apr 4. PMID: 27042841.
  47. Martino M, Montanari M, Bruno B, Console G, Irrera G, Messina G, Offidani M, Scortechini I, Moscato T, Fedele R, Milone G, Castagna L, Olivieri A. Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. Expert Opin Biol Ther. 2012 Nov;12(11):1449-62. doi: 10.1517/14712598.2012.707185. Epub 2012 Jul 13. PMID: 22788745.
  48. Dytfeld D, Łojko-Dankowska A, Nowicki A, Matuszak M, Wache A, Gil L. Safety and cost effectiveness of outpatient autologous hematopoietic stem cell transplantation for multiple myeloma - singlecenter experience of a pilot Early Discharge Program. Acta Haematol Pol. 2021; 52(3): 178-181. doi: 10.5603/ AHP.a2021.0029·
  49. Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 2015 Jul;50(7):947-53. doi: 10.1038/bmt.2015.46. Epub 2015 Apr 13. PMID: 25867651; PMCID: PMC4490016.
  50. Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C. Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art. Front Oncol. 2020 Nov 11;10:592487. doi: 10.3389/fonc.2020.592487. PMID: 33262948; PMCID: PMC7686536.
  51. Khouri J, Majhail NS. Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma. Curr Opin Support Palliat Care. 2017 Dec;11(4):361-365. doi: 10.1097/SPC.0000000000000305. PMID: 28922292.
  52. Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Nasta SD, Loren A, Frey N, Perl A, Cohen AD, Weiss BM, Stadtmauer EA, Vogl DT. Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):536-40. doi: 10.1016/j.clml.2015.05.006. Epub 2015 Jun 6. PMID: 26141214.
  53. Abid MB, Christopher D, Abid MA, Poon ML, Tan LK, Koh LP, Chng WJ. Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore. Bone Marrow Transplant. 2017 Jul;52(7):1044-1046. doi: 10.1038/bmt.2017.77. Epub 2017 May 8. PMID: 28481354.
  54. Lisenko K, Sauer S, Bruckner T, Egerer G, Goldschmidt H, Hillengass J, Schmier JW, Shah S, Witzens-Harig M, Ho AD, Wuchter P. High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. BMC Cancer. 2017 Feb 22;17(1):151. doi: 10.1186/s12885-017-3137-4. PMID: 28228122; PMCID: PMC5322605.
  55. Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A, O'Gara K, Rademaker A, Bennett C, Winter JN. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant. 2002 Dec;30(11):741-8. doi: 10.1038/sj.bmt.1703676. PMID: 12439696.
  56. Larsen K, Spencer H, Mohan M, Bailey C, Hill K, Kottarathara M, Parikh R, Hoque S, Erra A, Mitma AA, Mathur P, Yarlagadda L, Gundarlapalli S, Ogunsesan Y, Hussain M, Thalambedu N, Sehti J, Al Hadidi S, Thanendrarajan S, Graziutti M, Zangari M, Barlogie B, van Rhee F, Tricot G, Schinke C. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. J Clin Med. 2022 Mar 16;11(6):1640. doi: 10.3390/jcm11061640. PMID: 35329966; PMCID: PMC8955129.
  57. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, Bracy D, Jones R, Crowley J, Tricot G, Barlogie B. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 1997 Sep;20(6):445-50. doi: 10.1038/sj.bmt.1700900. PMID: 9313876.
  58. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, Kumar S, Lacy MQ, Leung N, Micallef IN, Porrata LF, Schafer BA, Wolf RC, Litzow MR. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc. 2008 Oct;83(10):1131-8. doi: 10.4065/83.10.1131. PMID: 18828972.
  59. Martino M, Russo L, Martinello T, Gallo GA, Fedele R, Moscato T, Console G, Vincelli DI, Ronco F, Postorino M, Irrera G, Messina G. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study. Leuk Lymphoma. 2015 Mar;56(3):801-4. doi: 10.3109/10428194.2014.931952. Epub 2014 Jul 17. PMID: 24913501.
  60. Ferrara F, Izzo T, Criscuolo C, Riccardi C, Viola A, Delia R, Carbone A, Celentano M. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol. 2011 Sep;29(3):139-43. doi: 10.1002/hon.978. Epub 2010 Nov 30. PMID: 21922508.
  61. Faucher C, Le Corroller Soriano AG, Esterni B, Vey N, Stoppa AM, Chabannon C, Mohty M, Michallet M, Bay JO, Genre D, Maraninchi D, Viens P, Moatti JP, Blaise D. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplant. 2012 Apr;47(4):549-55. doi: 10.1038/bmt.2011.126. Epub 2011 Jul 4. PMID: 21725375.
  62. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 May;27(9):893-8. doi: 10.1038/sj.bmt.1703015. PMID: 11436099.
  63. Cogbill CH, Drobyski WR, Komorowski RA. Gastrointestinal pathology of autologous graft-versus-host disease following hematopoietic stem cell transplantation: a clinicopathological study of 17 cases. Mod Pathol. 2011 Jan;24(1):117-25. doi: 10.1038/modpathol.2010.163. Epub 2010 Oct 15. PMID: 20953169.
  64. Nellen RG, van Marion AM, Frank J, Poblete-Gutiérrez P, Steijlen PM. Eruption of lymphocyte recovery or autologous graft-versus-host disease? Int J Dermatol. 2008 Nov;47 Suppl 1:32-4. doi: 10.1111/j.1365-4632.2008.03956.x. PMID: 18986483.
  65. Drobyski WR, Hari P, Keever-Taylor C, Komorowski R, Grossman W. Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. Bone Marrow Transplant. 2009 Jan;43(2):169-77. doi: 10.1038/bmt.2008.295. Epub 2008 Sep 1. PMID: 18762759.
  66. Porrata LF. Clinical evidence of autologous graft versus tumor effect. Am J Immunol. 2009; 5(1): 1-7. doi: 10.3844/ajisp.2009.1.7
  67. Vaxman I, Gertz M. Risk adapted post-transplant maintenance in multiple myeloma. Expert Rev Hematol. 2019 Feb;12(2):107-118. doi: 10.1080/17474086.2019.1576521. PMID: 30696304.
  68. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138. PMID: 22571202.
  69. Manasanch EE. Recommend maintenance therapy with lenalidomide in multiple myeloma. Semin Oncol. 2016 Dec;43(6):712-713. doi: 10.1053/j.seminoncol.2016.11.002. Epub 2016 Nov 5. PMID: 28061994.
  70. Goldschmidt H, Mai EK, Dürig J, Scheid C, Weisel KC, Kunz C, Bertsch U, Hielscher T, Merz M, Munder M, Lindemann HW, Hügle-Dörr B, Tichy D, Giesen N, Hose D, Seckinger A, Huhn S, Luntz S, Jauch A, Elmaagacli A, Rabold B, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab MS, Blau IW, Hänel M, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG). Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020 Jul;34(7):1853-1865. doi: 10.1038/s41375-020-0724-1. Epub 2020 Feb 7. PMID: 32034285.
  71. Holstein SA, Suman VJ, Hillengass J, McCarthy PL. Future Directions in Maintenance Therapy in Multiple Myeloma. J Clin Med. 2021 May 24;10(11):2261. doi: 10.3390/jcm10112261. PMID: 34073689; PMCID: PMC8197068.
  72. McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25. PMID: 28742454; PMCID: PMC5652871.
  73. Syed YY. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT. Drugs. 2017 Sep;77(13):1473-1480. doi: 10.1007/s40265-017-0795-0. PMID: 28791622.
  74. Uyl-de Groot CA, Ramsden R, Lee D, Boersma J, Zweegman S, Dhanasiri S. Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment. Eur J Haematol. 2020 Nov;105(5):635-645. doi: 10.1111/ejh.13497. Epub 2020 Sep 12. PMID: 32705720; PMCID: PMC7590122.
  75. Baertsch MA, Mai EK, Hielscher T, Bertsch U, Salwender HJ, Munder M, Fuhrmann S, Dührsen U, Brossart P, Neben K, Schlenzka J, Kunz C, Raab MS, Hillengaß J, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Goerner M, Hoffmann M, Lindemann HW, Bernhard H, Blau IW, Scheid C, Besemer B, Weisel KC, Hänel M, Dürig J, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG). Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2021 Jan 7;11(1):1. doi: 10.1038/s41408-020-00390-3. PMID: 33414374; PMCID: PMC7791127.
  76. Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulos S, Kang Y, Long GD, Horwitz ME, Lopez RD, Sullivan KM, Rizzieri DA, Chao NJ, Gasparetto C. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb;23(2):262-268. doi: 10.1016/j.bbmt.2016.11.010. Epub 2016 Nov 14. PMID: 27856369.
  77. Bird SA, Jackson GH, Pawlyn C. Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. Clin Hematol Int. 2020 May 20;2(2):59-68. doi: 10.2991/chi.d.200502.001. PMID: 34595444; PMCID: PMC8432350.
  78. Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2012 Mar;18(3):486-92. doi: 10.1016/j.bbmt.2011.12.580. Epub 2011 Dec 22. PMID: 22198542.
  79. Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020 Feb 13;10(2):17. doi: 10.1038/s41408-020-0273-x. PMID: 32054831; PMCID: PMC7018731.
  80. Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17. PMID: 26282661.
  81. D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14. PMID: 30447931.
  82. Ozaki S, Handa H, Koiso H, Saitoh T, Sunami K, Ishida T, Suzuki K, Narita T, Iida S, Nakamura Y, Suzuki K, Nishimura N, Murakami H, Shimizu K. Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. J Cancer Res Clin Oncol. 2022 Jan;148(1):191-203. doi: 10.1007/s00432-021-03668-6. Epub 2021 Jun 2. PMID: 34080068.

Bonello F, Cetani G, Bertamini L, Gay F, Larocca A. Moving Toward Continuous Therapy in Multiple Myeloma. Clin Hematol Int. 2019 Nov 12;1(4):189-200. doi: 10.2991/chi.d.191101.001. PMID: 34595430; PMCID: PMC8432368.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?